Navigation Links
The Psyche Behind Drug Commercials

Advertisements play a vital role in the life of common man. They are intended to boost the sale of any product from a small toy to a big automobile. When it comes to promoting// drugs through commercials, the campaigns are so credible that the consumers go for it even if they don’t need them.

This was revealed in a survey conducted by a group of researchers under Dominick L Frosch of University of California – Los Angeles Department of Medicine. This group has arrived at a few interesting conclusions after studying many commercials.

According to them, majority of the advertisements do a vigorous selling of the drug; a few of them indicate the risk factors and causes in nebulous terms. Life style changes have never been attributed to any sickness. Only a few of them relate that as an alternate to medicines. Physical activity has been demonstrated in almost all the advertisements which are very encouraging. The results about the use of a particular drug have been exaggerated from a social approval angle. This study feels that the pharma companies should exercise caution in the content of the advertisement too.

Reacting to this study, the Pharmaceutical Research and Manufacturer’s Association said that the advertisements increase the awareness about a disease and its treatment among the people.
JT
'"/>




Page: 1

Related medicine news :

1. The Logic Behind The Spread Of SARS
2. Understanding The Mystery Behind Sleepless Nights
3. Scientists Unveil Mechanism Behind Resistance to Severe Malaria
4. Researchers Find Out The Cause Of Immune Attacks Behind Hearing Loss
5. Molecule Behind Multiple Sclerosis Discovered
6. Annual Dental Checkups in Children Lagging Behind
7. Mystery Behind The Déjà Vu Phenomenon Yet To Be Resolvd
8. NHS Says Government Advice Behind Refusal of Cancer Drug
9. Know The Brain Behind The Human Growth Hormone!
10. Vital Facts of Short Term Diets - Catch The Vitamin Behind An Ample Waist!
11. The Secret Behind Extension of Earthly Life
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: The Psyche Behind Drug Commercials

Breaking Medicine Technology:Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 2Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 3Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 4Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 5Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 6Dynatronics Receives 180-Day NASDAQ Extension 2Nearly 100 HIV/AIDS Drugs and Vaccines in Development Pipeline 2NxStage Extends Supply Agreement with B Braun Medical Inc to Include Streamline 28R 29 Technology 47454 1NxStage Extends Supply Agreement with B Braun Medical Inc to Include Streamline 28R 29 Technology 47454 2NxStage Extends Supply Agreement with B Braun Medical Inc to Include Streamline 28R 29 Technology 47454 3AGA Institute and Horizon Therapeutics Launch Connect to Protect Program to Educate Physicians and Consumers on Risks Associated With NSAID Use 12385 1AGA Institute and Horizon Therapeutics Launch Connect to Protect Program to Educate Physicians and Consumers on Risks Associated With NSAID Use 12385 2AGA Institute and Horizon Therapeutics Launch Connect to Protect Program to Educate Physicians and Consumers on Risks Associated With NSAID Use 12385 3Shire Presented Results of a New Database Analysis on Lialda 28R 29 28Mesalamine 29 and Other 5 ASAs for Ulcerative Colitis at Digestive Disease Week 4503 1Shire Presented Results of a New Database Analysis on Lialda 28R 29 28Mesalamine 29 and Other 5 ASAs for Ulcerative Colitis at Digestive Disease Week 4503 2Shire Presented Results of a New Database Analysis on Lialda 28R 29 28Mesalamine 29 and Other 5 ASAs for Ulcerative Colitis at Digestive Disease Week 4503 3Shire Presented Results of a New Database Analysis on Lialda 28R 29 28Mesalamine 29 and Other 5 ASAs for Ulcerative Colitis at Digestive Disease Week 4503 4Shire Presented Results of a New Database Analysis on Lialda 28R 29 28Mesalamine 29 and Other 5 ASAs for Ulcerative Colitis at Digestive Disease Week 4503 5